The sponsors of three new products in the later stages of the EU evaluation process may appear this week before the European Medicine Agency's human medicines committee, the CHMP, to address outstanding concerns the committee has regarding their marketing applications.
Two companies seeking to extend the indications of already marketed products may also appear before the committee to address issues...








